EMAIL THIS PAGE TO A FRIEND

Melanoma research

In-vitro melanoma models: invasive growth is determined by dermal matrix and basement membrane.


PMID 24892959

Abstract

A critical first step in the metastatic progression of cutaneous melanoma, invasive growth into the dermal compartment, would ideally be studied in the proper three-dimensional tissue microenvironment. In this study, we compared the growth and behavior of four melanoma cell lines originating from primary and metastatic human cutaneous melanomas (AN, RU, M14, and WK) in in-vitro human skin equivalents (HSEs) generated with four different dermal matrices: human fibroblast-seeded rat tail collagen, human fibroblast-derived matrix (FDM), noncellular human de-epidermized dermis (DED), and a novel fully cellular human DED with an intact pre-existent basement membrane. Melanoma cells showed proliferation in all HSEs, indicating that the microenvironment formed in all HSEs studied here allows the growth of melanoma cells in concert with epidermal keratinocytes for multiple weeks in vitro. Melanoma cells did not affect epidermal proliferation and terminal differentiation. Growth of melanoma cells in the dermal compartment, as a measure of invasive potential, differs markedly between the four types of in-vitro human melanoma models. Notably, the growth of melanoma cells in the dermal matrix was observed in all HSEs cultured with cell lines originating from metastatic melanoma, except for cDED-based HSEs, and the growth of melanoma cells of nonmetastatic origin was observed in the dermal compartment of FDM-based HSEs. Our results show that the type of dermal equivalent and the presence of an intact basement membrane should be taken into consideration when studying melanoma invasion using in-vitro HSEs.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

A9673
Arachidonic acid, from porcine liver, ≥99% (GC), liquid
C20H32O2
A3555
Arachidonic acid, from porcine liver, BioReagent, suitable for cell culture, ≥99% (GC)
C20H32O2
A3925
Arachidonic acid, from porcine liver, ≥85% (capillary GC), liquid
C20H32O2
10931
Arachidonic acid, >95.0% (GC)
C20H32O2
A3611
Arachidonic acid, from non-animal source, ≥98.5% (GC)
C20H32O2
C0158
L-Carnitine inner salt, synthetic, ≥98%
C7H15NO3
S4500
L-Serine, ReagentPlus®, ≥99% (HPLC)
C3H7NO3
RES0908S-A7
L-Serine, PharmaGrade, Ajinomoto, EP, USP, JP, Manufactured under appropriate controls for use in pharma or biopharmaceutical production, suitable for cell culture
C3H7NO3
S4311
L-Serine, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%
C3H7NO3
84959
L-Serine, BioUltra, ≥99.5% (NT)
C3H7NO3
54763
L-Serine, certified reference material, TraceCERT®
C3H7NO3
84960
L-Serine, ≥99.0% (NT)
C3H7NO3
78682
L-Serine, tested according to Ph.Eur.
C3H7NO3
PHR1103
L-Serine, Pharmaceutical Secondary Standard; Certified Reference Material
C3H7NO3
S1315
L-Serine, PharmaGrade, Ajinomoto, EP, USP, manufactured under appropriate GMP controls for Pharma or Biopharmaceutical production, suitable for cell culture
C3H7NO3
1359903
Levocarnitine, United States Pharmacopeia (USP) Reference Standard
C7H15NO3
L0399900
Levocarnitine, European Pharmacopoeia (EP) Reference Standard
C7H15NO3
L1376
Linoleic acid, ≥99%
C18H32O2
L1012
Linoleic acid, liquid, BioReagent, suitable for cell culture
C18H32O2
L1268
Linoleic acid, ≥93% (GC)
C18H32O2
62230
Linoleic acid, analytical standard
C18H32O2
W338001
Linoleic acid, ≥95%
C18H32O2
62240
Linoleic acid, technical, 60-74% (GC)
C18H32O2
P5585
Palmitic acid, BioXtra, ≥99%
C16H32O2
P0500
Palmitic acid, ≥99%
C16H32O2
P0625
Palmitic acid, Grade II, ~95%
C16H32O2
43051
Palmitic acid, certified reference material, TraceCERT®
C16H32O2
1492007
Palmitic acid, United States Pharmacopeia (USP) Reference Standard
C16H32O2
76119
Palmitic acid, analytical standard
C16H32O2
27734
Palmitic acid, ≥98% palmitic acid basis (GC)
C16H32O2